36 results about "Renal ischemia reperfusion" patented technology

We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and / or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.

The invention relates to the field of medicine technology and provides an injection for curing ischemic-reperfusion damage of brain, heart, kidney and other tissue organs. The preparation method includes placing a medical injection flexible bag under low pressure for degasification, carrying out low-temperature pretreatment after air extraction, then injecting hydrogen for pressurized dissolution and dissolving hydrogen in the injection and storing under constant pressure and about 4 DEG C for standby. The injection can be used after 24-hour stabilization. The animal experiment proves that the injection of the invention can reduce focal cerebral ischemic-reperfusion damage in rats, neuron injuries and apoptosis number, decrease the activity of apoptosis enzyme in pallium and hippocampus, reduce the ischemic-reperfusion damage extent of heart and kidney and protect the function of ischemic-reperfusion heart and kidney. The hydrogen-included injection can be used as the medicine for curing the ischemic-reperfusion damages of brain, heart, kidney and other important organs.

The invention provides application of N6-(2-ethoxy)adenosine in preparation of preparations for treating renal failure. By virtue of the N6-(2-ethoxy) adenosine, levels of inosine and urea nitrogen in renal failure and renal ischemia reperfusion injury can be obviously reduced, and renal tubular epithelial cell apoptosis and kidney inflammations are inhibited. The N6-(2-ethoxy) adenosine can be applied to multiple treatment applications of renal failure, renal transplant, renal ischemia reperfusion injury, kidney stone lithotripsy inflammations and other nephritides.

The invention relates to a short peptide having a kidney protection function as well as a preparation method and application thereof. The short peptide having the kidney protection function is characterized in that the amino acid sequence of the short peptide is QEQLERALNSS. The preparation method is characterized by comprising the following steps: successively coupling Ser, Asn, Leu, Ala, Arg, Glu, Leu, Gln, Glu and Gln on serine which is based on resin as a vector; after cracking, and settling with ice ether so as to obtain coarse peptide; and purifying with a high performance liquid chromatography (HPLC) so as to obtain the product. The invention also discloses application of the short peptide having the kidney protection function in the aspects of preparing formulations for treating renal ischemia-reperfusion injury along with acute tubular necrosis, local renal tissue inflammation and renal tubular epithelium cell apoptosis which are caused by the renal ischemia-reperfusion injury. The invention provides a novel clinic medicament for preventing and treating the renal ischemia-reperfusion injury, thereby bringing good news for patients suffering renal transplant.

The present invention relates to application of N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as an adenosine A1 receptor agonist in preparation of drug or food, the HEA and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, Parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney.

We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and / or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.

The invention belongs to the technical field of kidney injury treatment drugs, and particularly relates to application of ponatinib as a drug for acute kidney injury. As an acute clinical complication, the acute kidney injury has the characteristics of being high in morbidity and high in mortality, and effective treatment drugs are not achieved at present. Related researchers in the field show that PDCD4 expression becomes higher in an acute kidney injury model, and it is indicated that the PDCD4 plays an important role in the physiological mechanism related to the acute kidney injury. The situation that the PDCD4 aggravates the kidney injury by regulating an Fgr-Stat3-Notch1 pathway is further confirmed. The confirmation of the regulatory mechanism provides a basis for the treatment of the acute kidney injury. According to the research results, the ponatinib, an Fgr kinase inhibitor, is adopted to treat the acute kidney injury, the drug has a significant protective effect on the injury caused by kidney ischemia reperfusion, and it is indicated that the drug intervention in Fgr can prevent and treat the acute kidney injury.

The invention provides a polypeptide having a kidney protection effect. The polypeptide is characterized in that the structural general formula of the sequence of the polypeptide is X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-R2, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10 and X11 are independently L- or D-type natural alkaline, acidic or aromatic amino acids or derivatives thereof, the above amino acids are selected from Cys, Ser, Asn, Leu, Ala, Arg, Glu and Gln, and R2 is hydrogen or an amino group. The polypeptide can be used for treating the renal ischemia reperfusion injury.

The invention provides a preparation method and application of an ROS-sensitive and H2S donor-responsive nano-micelle. The preparation method comprises the following steps that step 1, a reaction solution 1 is prepared, a reaction solution 2 is prepared, and the reaction solution 2 is dropwise added into the reaction solution 1 to obtain a reaction solution 3; step 2, impurities are removed through a dialysis method, and an HATM freeze-dried product is obtained through freeze-drying; and step 3, the HATM freeze-dried product and rapamycin are weighed, the HATM freeze-dried product and the rapamycin are dissolved in DMF, HATM@RAP is formed in a self-assembly mode, and non-entrapped free drugs are removed. According to the preparation method of the ROS-sensitive and H2S donor-responsive nano-micelle, hyaluronic acid is specifically combined with a CD44 receptor on the surface of the macrophage, so that the drug is gathered at the renal ischemia reperfusion injury part, and the targeting effect is realized; a ROS sensitive group is introduced, so that when a novel drug delivery system reaches a part with higher ROS concentration, the drug can be quickly released, and the effect of quick treatment is realized; and by introducing an H2S donor, H2S can be slowly released at the kidney part, and finally, the effects of preventing inflammatory injury and promoting renal ischemia reperfusion protection are achieved.

The invention discloses a two-stage targeted polymeric pro-drug for treating acute kidney injury and a preparation method and belongs to the field of medicines. The polymeric pro-drug is prepared by grafting (4-carboxybutyl) triphenyl phosphonium bromide, curcumin and low molecular weight chitosan of different polymerization degrees. According to the polymeric pro-drug, the low molecular weight chitosan is combined with a Megalin receptor which is specifically expressed on the surface of renal tubular epithelial cells, and distribution of the curcumin in target cells is increased; under medication of mitochondrion target molecules (4-carboxybutyl) triphenyl phosphonium bromide, the polymeric pro-drug fed into cells further increases distribution of the curcumin in target cell mitochondria,and by reducing ROS (reactive oxygen species) generated by the mitochondria, oxidative stress injury of the renal tubular epithelial cells can be effectively reversed, and targeted therapy on ischemia reperfusion injury can be achieved.

The invention relates to application of TRPC6 in preparation of a medicament for diagnosing and treating kidney ischemic reperfusion injury. The inventor researches the effect of the TRPC6 for regulating and controlling necroptosis in the kidney I / R (ischemic reperfusion) and a mechanism of the TRPC6 according to the relation between ion channel proteins and the kidney I / R injury, so that the effect of a signal passageway from TRPC6Ca to ions, then to CaMKII, and lastly to PARP-1 in the kidney ischemic reperfusion injury is achieved, a new idea and a new therapeutic target are provided for prevention and treatment of the kidney I / R, and the TRPC6 has an important practical application value.

The invention provides a multifunctional liposome based on ROS sensitivity and H2S response as well as a preparation method and application of the multifunctional liposome. The multifunctional liposome comprises a PFC carrier, phospholipid and cholesterol, wherein ROS reaction groups and H2S donors are introduced into the PFC carrier through chemical bonds; meanwhile, the invention also entraps hydroxysafflor yellow A; the mass ratio of the phospholipid to the hydroxysafflor yellow A is (2-4): 1; the molar ratio of the phospholipid to the PFC carrier is (4-8): 1. The ROS reactive group and the H2S donor are introduced into the PFC carrier, and the liposome prepared by using the PFC carrier has ROS sensitivity and H2S response functions. The liposome simultaneously entraps a strong water-soluble drug hydroxysafflor yellow A, so that the slow release time of HSYA is prolonged, the cell penetrating ability of HSYA is improved, and the renal ischemia reperfusion injury is treated in multiple aspects.

The effects of hepcidin treatment on mitigating renal ischemiareperfusion injury (IRI) and acute kidney injury (AKI) by decreasing iron availability and ROS-mediated cell death were tested. C57Bl / 6 (WT) and hepcidin knock out (Hamp− / −) mice were treated with saline or 50 μg of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-heme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-theme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis. These results demonstrate a protective role of hepcidin in IRI and AKI.

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-γ / IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.

The invention discloses a Chinese medicinal composition for preventing and treating renal ischemia reperfusion injury. The Chinese medicinal composition is mainly prepared from the following raw materials in parts by weight: 50-70 parts of galium aparine, 8-12 parts of radix notoginseng, 12-18 parts of semen coicis, 8-12 parts of prepared rheum officinale, 12-18 parts of radix astragali and 4-8 parts of radix glycyrrhizae. A preparation method of the Chinese medicinal composition for preventing and treating renal ischemia reperfusion injury mainly comprises the following steps: drying the galium aparine; mixing the prepared rheum officinale, the radix astragali and the radix glycyrrhizae, smashing the mixture, and performing trapezoidal reflux extraction on the smashed mixture with ethanol; smashing the galium aparine, and performing ultrasonic wave-assisted water extraction and ethanol reflux extraction on the smashed galium aparine; performing superfine grinding on the radix notoginseng and the semen coicis, and performing ultrasonic wave-assisted alcohol extraction; combining and concentrating extraction solutions. The Chinese medicinal composition has the effects of clearing heat, promoting diuresis, promoting blood circulation to remove blood stasis, eliminating evil without injuring healthy energy and strengthening healthy energy without retaining evil, and has remarkable prevention and treatment effects on renal ischemia reperfusion injury.

A method for preventing or treating renal ischemia reperfusion injury or acute kidney injury associated with renal ischemia reperfusion injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

A compound amino acid composition for protecting the kidney contains glycine, alpha-alanine, threonine, serine, leucine, isoleucine, proline, etc, and can be used to prepare the medicine in the form injection, powder, tablet, or capsule for treating the acute renal dysfunction caused by cisplatin medicines and ischemia. Its advantage is high curative effect.

The invention provides an application of a recombinant human myeloid-derived growth factor in preparation of a medicine for treating renal ischemia reperfusion injury. The recombinant human medullary-derived growth factor can reduce serum creatinine and urea nitrogen levels of mice suffering from renal ischemia reperfusion injury, improves renal functions after renal ischemia reperfusion injury, has a kidney protection effect and can relieve oxidative stress injury caused by renal ischemia reperfusion injury. The traditional Chinese medicine composition brings hopes for improving the life quality of kidney transplantation patients and prolonging the survival time of transplanted kidneys, and also has a certain far-reaching influence on prevention and treatment of ischemia reperfusion injuries of other tissues and organs.

The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I / R) in a mammal, preferably in a critically ill patient suffering from acute stress.

The invention provides application of naringenin in preparation / protection of renal ischemia reperfusion injury through relieving of renal inflammatory response, and belongs to the field of biologicalmedicines. The application proves that the naringenin is capable of preventing / protecting human acute kidney injury caused due to ischemia reperfusion, and a protection effect of the naringenin is achieved through the relieving of the renal inflammatory response; the application further proves, through bioinformatics, that an action mechanism of the naringenin is relevant with direct bonding of NF-kB associated proteins; and finally, experiments prove that the expression amount of NF-kB is decreased after the application of the naringenin, so that a theoretical basis is provided for broadening the possible application range of the naringenin. The naringenin can be applied to theoretical researches and clinic treatments on the renal ischemia reperfusion injury, thereby providing an idea for exploration of prevention and / or protection effects of traditional Chinese medicines to the acute kidney injury caused due to the ischemia reperfusion.

The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

The invention discloses an application of GW3965 for preparation of medicines preventing and treating kidney ischemia reperfusion injuries. The GW3965 is a selective LXR agonist, and acts on LXR[alpha] and LXR[beta]. Significant medicine effects of the GW3965 allow the GW3965 to have a potential for development into as a medicine preventing and treating kidney injuries, and allow the GW3965 to be a research direction of new medicines preventing and treating kidney injuries.

The invention relates to the technical field of biomedicine, in particular to tetranectin-mimicking peptide TNP and its application in treating diseases caused by the release of HMGB1 from vascular endothelial cells. The sequence of the acetylated tetranectin mimetic peptide at the nitrogen end is Ac‑QPDGGKTENCAVLSGAANGKWFDKRCRDK‑biotin. The acetylated tetranectin mimetic peptide TNP can effectively prevent the hydrolysis of TNP and prolong its half-life to improve the biological efficacy of the drug. TNP is in use When preparing drugs for the treatment of sepsis and other diseases, it can effectively inhibit the release of HMGB1 from vascular endothelial cells, reduce the concentration of extracellular HMGB1, and reduce the death rate of septic mice, and can almost completely block renal ischemia-reperfusion in mice. Changes in plasma urea nitrogen and creatinine can reduce renal tubular necrosis after ischemia, achieve the purpose of treating acute kidney injury, and provide a new way for the diagnosis and treatment of human diseases caused by the release of HMGB1 from vascular endothelial cells.

An application of Ponatinib as a drug for acute kidney injury. Since PDCD4 aggravates the kidney injury by regulating an Fgr-Stat3-Notch1 pathway, the ponatinib, an Fgr kinase inhibitor, is adopted to treat the acute kidney injury. The drug has a significant protective effect on the injury caused by kidney ischemia reperfusion, and it is indicated that the drug intervention in Fgr can prevent and treat the acute kidney injury.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute kidney injuries. The effective ingredients of the traditional Chinese medicine composition are prepared from, by weight, 1-2 parts of borneol, 1-2 parts of musk, 3-5 parts of cooptis chinensis, 3-5 parts of scutellaria baicalensis, 3-5 parts of fructus gardenia, 3-5 parts of radix curcumae, 1-3 parts of pearls, 7-9 parts of concentrated cornu bubali powder and 3-5 parts of calculus bovis. The pharmacodynamics study shows that the traditional Chinese medicine composition has a remarkable protection function on mouse acute kidney injuries caused by kidney ischemia reperfusion, vancomycin and cis-platinum, increase of blood urea nitrogen, serum creatinine, TNF-alpha and IL-1beta caused by the kidney injuries can be remarkably reduced, the content of serum malonaldehyde and NO in kidney tissue is reduced, and the sudismase level in the kidney tissue is improved.

The invention provides a traditional Chinese medicine composition and its application in the preparation of medicines for treating acute kidney injury; the active ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in parts by weight: 1-2 parts of borneol, 1-2 parts of musk 3-5 parts of Coptis chinensis, 3-5 parts of Scutellaria baicalensis, 3-5 parts of gardenia, 3-5 parts of turmeric, 1-3 parts of pearl, 7-9 parts of concentrated buffalo horn powder, 3-5 parts of bezoar. The results of pharmacodynamic studies show that the traditional Chinese medicine composition has a significant protective effect on acute kidney injury in mice caused by renal ischemia-reperfusion, vancomycin, and cisplatin, and can significantly reduce blood urea nitrogen caused by renal injury. , serum creatinine, TNF-α and IL-1β increase, reduce serum malondialdehyde and NO content in renal tissue, and increase superoxide dismutase level in renal tissue.

The present invention relates to application of N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as an adenosine A1 receptor agonist in preparation of drug or food, the HEA and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, Parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney.

The invention discloses a near-infrared molecular probe capable of reversibly responding to ClO <-> / GSH oxidation reduction as well as a preparation method and application of the near-infrared molecular probe. According to the invention, the near-infrared probe aza-BODIPY (AzaBDP-DiOH) is obtained through preparation methods such as aldol condensation, Michael addition and cyclization reaction, and the molecular formula of the aza-BODIPY (AzaBDP-DiOH) is C50H56BF2N3O4. The near-infrared probe AzaBDP-DiOH prepared by the method disclosed by the invention can be specifically oxidized into AzaBDP-DiO by ClO <->, the ultraviolet absorption of the near-infrared probe AzaBDP-DiO at 682nm is weakened, and the ultraviolet absorption of the near-infrared probe AzaBDP-DiO at 965nm is enhanced; azaBDP-DiO can be specifically reduced into AzaBDP-DiOH by GSH, the ultraviolet absorption of the AzaBDP-DiOH at 965nm is weakened, and the ultraviolet absorption at 682nm is enhanced, so that the probe shows good selectivity and sensitivity on ClO- / GSH, meanwhile, the probe is successfully used for in-vivo renal ischemia reperfusion mouse model visual imaging, and the probe has good application prospects in the aspect of monitoring ClO- / GSH oxidation reduction.

The invention provides a polypeptide having a kidney protection effect. The polypeptide is characterized in that the structural general formula of the sequence of the polypeptide is X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-R2, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10 and X11 are independently L- or D-type natural alkaline, acidic or aromatic amino acids or derivatives thereof, the above amino acids are selected from Cys, Ser, Asn, Leu, Ala, Arg, Glu and Gln, and R2 is hydrogen or an amino group. The polypeptide can be used for treating the renal ischemia reperfusion injury.